



In Vitro Activity of Sulopenem, An Oral Penem, against *Escherichia coli* Isolated from Urine Specimens of Patients Across Canada in 2014-2016

G.G. ZHANEL¹, H.J. ADAM^{1,2}, M.R. BAXTER¹, A.J. DENISUIK¹, P. LAGACE-WIENS², A. WALKTY², D.J. HOBAN^{1,2}, S. PUTTAGUNTA³, M. DUNNE³, J.A. KARLOWSKY²

¹University of Manitoba, ²Shared Health, Winnipeg, MB, Canada; ³Iterm Therapeutics, Old Saybrook, CT, USA



Dr. George G. Zhanel
Department of Medical Microbiology
Max Rady College of Medicine
MS673-820 Sherbrook St.
Winnipeg, MB R3A 1R9
Email: ggzhanel@pcs.mb.ca

Abstract

Background: Sulopenem (SULO) is an investigational penem (β-lactam) available in both oral and parenteral dosage forms that is being developed for the treatment of infections caused by multidrug-resistant (MDR) and ESBL-producing Gram-negative bacilli. The current study assessed the *in vitro* activities of SULO and comparator antimicrobial agents against recent (2014-2016) urinary isolates of *E. coli* cultured from patient specimens by Canadian hospital laboratories as participants in the CANWARD study, an ongoing, national, Canadian study assessing antimicrobial resistance patterns of pathogens causing infections in patients receiving care in hospitals across Canada. **Methods:** SULO and comparator agent antimicrobial susceptibility testing was performed centrally by the CANWARD coordinating laboratory using CLSI-defined broth microdilution methodology. MICs were interpreted using CLSI M100, 27th Edition (2017) breakpoints. To date, 153 urinary isolates of *E. coli* from 2014-2016 have been tested, including ESBL-, AmpC-, and KPC-positive isolates. Antimicrobial susceptibility testing is ongoing. **Results:** The table shows MIC₅₀/MIC₉₀/MIC range data for SULO and MIC₉₀% susceptible data for selected comparator agents for 150 urinary isolates of *E. coli* from the CANWARD study stratified by antimicrobial resistance phenotypes/genotypes. Two additional, previously identified KPC-positive isolates of *E. coli* were also tested and generated SULO MICs of 8->8 µg/ml and meropenem MICs of 4-32 µg/ml. **Conclusion:** The SULO MIC₉₀ against urinary isolates of *E. coli* tested to date was 0.06 µg/ml, with a MIC range of 0.015-0.25 µg/ml. The *in vitro* activity of SULO was unaffected by concurrent non-susceptibility to trimethoprim-sulfamethoxazole, ciprofloxacin, the presence of ESBL or AmpC enzymes, or MDR phenotypes (excluding the two additional KPC-positive isolates tested).

E. coli Phenotype/Genotype	MIC ₅₀ /MIC ₉₀ /MIC Range (µg/ml)		MIC ₉₀ (µg/ml) % Susceptible				
	MERO	CTR	AMC	SXT	NIT	CIP	
All isolates (150)	0.03/0.06/0.015-0.25	≤0.03/100	>64/66.0	16/74.0	>8/64.0	16/95.3	>16/58.7
SXT-S (86)	0.03/0.06/0.015-0.12	≤0.03/100	>64/77.1	16/83.3	0.25/100	16/95.8	>16/78.1
SXT-NS (54)	0.03/0.06/0.015-0.25	≤0.03/100	>64/46.3	32/57.4	>8/0	32/94.4	>16/24.1
CIP-S (88)	0.03/0.03/0.015-0.12	≤0.03/100	32/85.2	16/89.8	>8/85.2	16/98.9	0.12/100
CIP-NS (62)	0.03/0.06/0.015-0.25	≤0.03/100	>64/38.7	32/51.6	>8/33.9	32/90.3	>16/0
SXT-NS & CIP-NS (41)	0.03/0.06/0.015-0.25	≤0.03/100	>64/43.9	32/51.2	>8/0	32/95.1	>16/0
ESBL-positive (49)	0.03/0.06/0.03-0.12	≤0.03/100	>64/2.0	32/55.1	>8/42.9	16/93.9	>16/24.5
AmpC-positive (4)	0.03-0.25	≤0.03-0.06	≤0.25->64	32->32	0.25->8	8-32	≤0.06->16
MDR (31)	0.03/0.06/0.03-0.25	≤0.03/100	>64/16.1	32/38.7	>8/6.5	64/87.1	>16/6.5

Abbreviations: S, susceptible; NS, non-susceptible; SULO, sulopenem; MERO, meropenem; CTR, ceftriaxone; AMC, amoxicillin-clavulanate; SXT, trimethoprim-sulfamethoxazole; NIT, nitrofurantoin; CIP, ciprofloxacin; MDR, multidrug-resistant, defined as resistance to ≥3 agents from different antimicrobial classes.

Introduction

Sulopenem, formerly CP-70,429, is an investigational penem β-lactam antimicrobial being developed for the treatment of infections caused by multidrug-resistant and ESBL-producing Gram-negative bacilli. It is available in both parenteral and oral prodrug formulations [1]. Unlike imipenem, sulopenem is stable to renal dehydropeptidase I [2].

The purpose of this study was to assess the *in vitro* activities of sulopenem and comparator antimicrobial agents against recent (2014-2016) urinary isolates of *E. coli* collected from patients receiving care in hospitals across Canada.

Materials and Methods

Bacterial Isolates

CANWARD is an ongoing study assessing antimicrobial resistance and pathogen prevalence in Canadian hospitals. Each hospital site was asked to submit clinical isolates (consecutive, one per patient per infection site) from inpatients and outpatients with respiratory, wound, urine and bloodstream infections. Isolates were collected from patients attending hospital clinics, emergency rooms, surgical/medical wards and intensive care units. Isolates were shipped to the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada) where they were subcultured onto appropriate media and stocked in skim milk at -80° C.

Antimicrobial Susceptibility Testing

539 urinary isolates of *E. coli* from 2014-2016 were tested, including ESBL-, AmpC-, and KPC-positive isolates. Sulopenem and comparator agent antimicrobial susceptibility testing was performed centrally by the CANWARD coordinating laboratory using broth microdilution and CLSI protocols [3]. MICs were interpreted using CLSI M100, 28th Edition (2018) breakpoints [4]. ESBLs were identified and confirmed following CLSI guidelines [4] and multidrug-resistant (MDR) isolates were defined using a published guideline [5].

Results

Table 1. *In vitro* activity of sulopenem and comparator agents against *E. coli* isolated from urine specimens of patients across Canada in 2014-2016.

Organism (no. tested) / Antimicrobial Agent	MIC (µg/mL)				%S	%I	%R	Organism (no. tested) / Antimicrobial Agent	MIC (µg/mL)				%S	%I	%R
	MIC ₅₀	MIC ₉₀	Range Min	Range Max					MIC ₅₀	MIC ₉₀	Range Min	Range Max			
All Isolates (539)								Ciprofloxacin Non-Susceptible (128)							
Sulopenem	0.03	0.03	0.015	0.12			NB	Sulopenem	0.03	0.06	0.015	0.12			NB
Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.12	100	0	0	Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.06	100	0	0
Ceftriaxone	≤ 0.25	1	≤ 0.25	> 64	90.4	0.1	9.5	Ceftriaxone	≤ 0.25	> 64	≤ 0.25	> 64	70.3	0	29.7
Amoxicillin/clavulanate	4	16	0.5	> 32	81.3	14.6	4.1	Amoxicillin/clavulanate	8	16	1	> 32	63.3	28.9	7.8
SXT	≤ 0.12	> 8	≤ 0.12	> 8	75.5	-	24.5	SXT	> 8	> 8	≤ 0.12	> 8	46.9	-	53.1
Nitrofurantoin	16	16	≤ 1	256	97.8	1.5	0.7	Nitrofurantoin	16	32	≤ 1	256	91.4	6.3	2.3
Ciprofloxacin	≤ 0.06	> 16	≤ 0.06	> 16	76.3	0.1	23.6	Ciprofloxacin	> 16	> 16	2	> 16	0	0.8	99.2
SXT-Susceptible (407)								SXT and Ciprofloxacin Non-Susceptible (68)							
Sulopenem	0.03	0.03	0.015	0.12			NB	Sulopenem	0.03	0.06	0.015	0.12			NB
Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.12	100	0	0	Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.06	100	0	0
Ceftriaxone	≤ 0.25	> 64	≤ 0.25	> 64	94.3	0	5.7	Ceftriaxone	≤ 0.25	> 64	≤ 0.25	> 64	66.2	0	33.8
Amoxicillin/clavulanate	4	16	0.5	> 32	88.0	9.1	2.9	Amoxicillin/clavulanate	8	32	2	> 32	55.9	33.8	10.3
SXT	≤ 0.12	0.25	≤ 0.12	2	100	-	0	SXT	> 8	> 8	4	> 8	0	-	100
Nitrofurantoin	16	16	≤ 1	128	98.3	1.2	0.5	Nitrofurantoin	16	32	≤ 1	256	94.1	4.4	1.5
Ciprofloxacin	≤ 0.06	> 16	≤ 0.06	> 16	85.3	0	14.7	Ciprofloxacin	> 16	> 16	2	> 16	0	1.5	98.5
SXT Non-Susceptible (132)								ESBL positive (49)							
Sulopenem	0.03	0.06	0.015	0.12			NB	Sulopenem	0.03	0.06	0.03	0.12			NB
Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.06	100	0	0	Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.06	100	0	0
Ceftriaxone	≤ 0.25	> 64	≤ 0.25	> 64	78.0	0.8	21.2	Ceftriaxone	> 64	> 64	1	> 64	2.0	2.1	95.9
Amoxicillin/clavulanate	8	16	2	> 32	60.6	31.8	7.6	Amoxicillin/clavulanate	8	32	4	> 32	55.1	32.7	12.2
SXT	> 8	> 8	4	> 8	0	-	100	SXT	> 8	> 8	≤ 0.12	> 8	42.9	-	57.1
Nitrofurantoin	16	32	≤ 1	256	96.2	2.3	1.5	Nitrofurantoin	16	16	2	256	93.9	2.0	4.1
Ciprofloxacin	16	> 16	≤ 0.06	> 16	48.5	0.7	50.8	Ciprofloxacin	> 16	> 16	≤ 0.06	> 16	24.5	0	75.5
Ciprofloxacin-Susceptible (411)								Multidrug-Resistant (47)							
Sulopenem	0.03	0.03	0.015	0.12			NB	Sulopenem	0.03	0.06	0.015	0.12			NB
Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.12	100	0	0	Meropenem	≤ 0.03	≤ 0.03	≤ 0.03	0.06	100	0	0
Ceftriaxone	≤ 0.25	≤ 0.25	≤ 0.25	> 64	96.6	0.2	3.2	Ceftriaxone	64	> 64	≤ 0.25	> 64	31.9	0	68.1
Amoxicillin/clavulanate	4	16	0.5	> 32	86.9	10.2	2.9	Amoxicillin/clavulanate	16	32	4	> 32	42.6	31.9	25.5
SXT	≤ 0.12	> 8	≤ 0.12	> 8	84.4	-	15.6	SXT	> 8	> 8	≤ 0.12	> 8	14.9	-	85.1
Nitrofurantoin	16	16	≤ 1	128	99.8	0	0.2	Nitrofurantoin	8	32	2	256	91.5	2.1	6.4
Ciprofloxacin	≤ 0.06	0.12	≤ 0.06	1	100	0	0	Ciprofloxacin	> 16	> 16	≤ 0.06	> 16	8.5	0	91.5

Multidrug-resistant (MDR) was defined as non-susceptible to ≥3 agents from different antimicrobial classes (amoxicillin/clavulanate, ceftriaxone, trimethoprim sulfa, ciprofloxacin, gentamicin, nitrofurantoin). NB, no breakpoints defined for sulopenem; SXT, trimethoprim-sulfamethoxazole.

Table 2. Distribution of sulopenem MICs for *E. coli* isolated from urine specimens of patients across Canada in 2014-2016.

Antimicrobial agent	Number of isolates for which the antimicrobial agent MIC (µg/ml) was:										Total
	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	
Sulopenem				67	425	40	7				539

Sulopenem was highly active against four tested AmpC-producing urinary *E. coli* isolates, with an MIC range of 0.03-0.12 µg/ml. Sulopenem did not demonstrate activity against two tested KPC-positive urinary *E. coli* isolates, with MIC values of ≥ 8 µg/ml.

Conclusions

1. Sulopenem demonstrates potent *in vitro* activity against urinary isolates of *E. coli*. The MIC₉₀ against tested isolates was 0.03 µg/ml, with a MIC range of 0.015-0.12 µg/ml.
2. The *in vitro* activity of sulopenem against urinary isolates of *E. coli* was unaffected by concurrent non-susceptibility to trimethoprim-sulfamethoxazole or ciprofloxacin.
3. The *in vitro* activity of sulopenem against urinary isolates of *E. coli* was unaffected by the presence of ESBL or AmpC enzymes, or MDR phenotypes (excluding the two additional KPC-positive isolates tested).
4. Sulopenem may represent a valuable treatment option for urinary *E. coli* with various antimicrobial resistance phenotypes, warranting further surveillance and clinical development.

Acknowledgements

The authors would like to thank the participating centres, investigators and laboratory site staff for their continued support:

Dr. D. Roscoe – Vancouver Hospital, Vancouver; Dr. J. Fuller – University of Alberta Hospital, Edmonton; Dr. J. Blondeau – Royal University Hospital, Saskatoon; Drs. D. Hoban/G. Zhanel – Health Sciences Centre, Winnipeg; Dr. J. Delport – London Health Sciences Centre, London; Dr. S. Poutanen – University Health Network & Mount Sinai Hospital, Toronto; Dr. L. Matukas – St. Michael's Hospital, Toronto; Dr. F. Chan – Children's Hospital of Eastern Ontario, Ottawa; Dr. M. Desjardins – The Ottawa Hospital, Ottawa; Dr. M. Bergevin – Cité de la Santé de Laval, Laval; Dr. M. Laverdière – Hôpital Maisonneuve-Rosemont, Montreal; Dr. M. Goyette – CHRTR Pavillon Ste. Marie, Trois-Rivières; Dr. A. Carigan – Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Dr. R. Pelletier – L'Hotel-Dieu de Quebec, Quebec City; Dr. C. Ellis – South East Regional Health Authority, Moncton; Dr. R. Davidson – Queen Elizabeth II HSC, Halifax.

This study was supported in part by the Health Sciences Centre, University of Manitoba, National Microbiology Laboratory, and Iterm Therapeutics.

References

1. Dunne M and Puttagunta S. Poster Saturday-296, ASM Microbe 2017. New Orleans, LA, June 1-5, 2017.
2. Minamimura M *et al.* *Antimicrob. Agents Chemother.* 1993; 378: 1547-51.
3. Clinical and Laboratory Standards Institute. *M07 11th Edition*. Wayne, PA. CLSI 2018.
4. Clinical and Laboratory Standards Institute. *M100 28th Edition*. Wayne, PA. CLSI 2018.
5. Magiorakos AP, *et al.* *Clin. Microbiol. Infect.* 2012; 18: 268-281.